How Risky Is Too Risky?
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Big Pharma biz dev execs discuss whether they would consider acquiring a product with a profile like Tysabri’s.
You may also be interested in...
Tysabri Sales Dip But Don’t Swoon After PML Adverse Events
Biogen plans to report further progressive multifocal leukoencephalopathy cases only when “they provide substantial new information,” CEO Mullen says.
Change of Control: Why Getting it Right Matters Even More
Private biotechs' growing dependence on an M&A exit and the more lively acquisition activity throughout the sector means change of control provisions are being far more heavily negotiated than in the past, and it's critical to understand how far-reaching these provisions could be for biotechs hoping for successful exits.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.